TRAW
Traws Pharma, Inc.
There isn't enough reported data to score TRAW yet.
TRAW Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TRAW's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
TRAW PE Valuation
TRAW has no meaningful PE right now: it lost money over the past year.
TRAW Forward outlook
There aren't enough analyst estimates for TRAW to show an outlook.
TRAW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.85 | +$26.27 |
| Q1 2026 | -$1.80 | +$147.96 |
| Q4 2025 | $0.82 | +$158.67 |
| Q3 2025 | -$19.65 | +$121.66 |
| Q2 2025 | -$28.12 | +$110.13 |
| Q1 2025 | -$149.76 | -$128.26 |
| Q4 2024 | -$157.85 | -$135.35 |
| Q3 2024 | -$141.31 | -$117.06 |
TRAW lost $1.85 per share over the past year, a smaller loss than the year before.
TRAW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $2.7M | +4695% |
| Q1 2025 | $57K | +1.8% |
| Q4 2024 | $56K | 0% |
| Q3 2024 | $57K | 0% |
| Q2 2024 | $57K | 0% |
| Q1 2024 | $56K | 0% |
| Q4 2023 | $56K | 0% |
| Q3 2023 | $57K | 0% |
TRAW's revenue has picked up after four years of holding roughly level: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -46% | +216354 points |
| Q1 2025 | -9128% | +179 points |
| Q4 2024 | -9425% | -1457 points |
| Q3 2024 | -14975% | -6047 points |
| Q2 2024 | -216400% | -208312 points |
| Q1 2024 | -9307% | +1652 points |
| Q4 2023 | -7968% | +2271 points |
| Q3 2023 | -8928% | +968 points |
TRAW's operating margin was −46% last quarter, up 216354 points from the same quarter a year ago, near the top of its range since 2019.
TRAW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.6M | +$2.9M |
| Q4 2025 | -$2.8M | +$1.3M |
| Q1 2025 | -$5.4M | -$1M |
| Q4 2024 | -$4M | +$390K |
| Q1 2024 | -$4.4M | +$119K |
| Q4 2023 | -$4.4M | -$546K |
| Q2 2023 | -$4.5M | -$276K |
| Q1 2023 | -$4.5M | -$247K |
TRAW has burned cash in almost every quarter: −$18M over the past year, against −$24M the year before.
TRAW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +49% | +5.2M shares |
| 1 year | +120% | +8.6M shares |
| 3 years | +1797% | +15M shares |
| 5 years | +3318% | +15.4M shares |
| Available history | +96762% | +15.8M shares |
TRAW has 16M diluted shares, up 120% from a year ago.
TRAW Net Leverage
TRAW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
TRAW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 5.5 | Oversold |
TRAW's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
TRAW PE vs Healthcare Sector
TRAW has no meaningful PE right now: it lost money over the past year.
TRAW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.39 | 28% below |
| 20 week MA | $0.50 | 44% below |
| 50 week MA | $1.19 | 76% below |
| 100 week MA | $2.12 | 87% below |
| 200 week MA | $9.74 | 97% below |
TRAW is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
TRAW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $153.8 | $176.3 | +15% |
| 2021 | $176.3 | $71.3 | -60% |
| 2022 | $71.3 | $16.5 | -77% |
| 2023 | $16.5 | $18.8 | +14% |
| 2024 | $18.8 | $13.4 | -28% |
| 2025 | $13.4 | $1.17 | -91% |
| 2026 YTD | $1.17 | $0.28 | -76% |
TRAW has finished lower in four of the last six years. It's down 76% so far in 2026.